ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

ClinicalTrials.gov ID: NCT05683496

Public ClinicalTrials.gov record NCT05683496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Study identification

NCT ID
NCT05683496
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
ACELYRIN Inc.
Industry
Enrollment
31 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • lonigutamab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 13, 2023
Primary completion
May 25, 2025
Completion
May 25, 2025
Last update posted
Jun 30, 2025

2023 – 2025

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Clinical Research Site Jacksonville Florida 32216
Clinical Research Site Atlanta Georgia 30328
Clinical Research Site Ann Arbor Michigan 48108
Clinical Research Site East Setauket New York 11733
Clinical Research Site New York New York 10028
Clinical Research Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05683496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 30, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05683496 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →